Patients’ Attitude to Subcutaneous Immunoglobulin Substitution As Home Therapy.

Patients’ Attitude to Sub-Q: Kittner et al

Patients’ attitude to subcutaneous immunoglobulin substitution as home therapy.
J Clin Immunol. 2006;26:400-405.

Kittner JM, Grimbacher B, Wulff W, Jäger B, Schmidt RE.

Clinical Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
kittner.jens@mh-hannover.de

INTRODUCTION: Since 2003, immunoglobulin preparations have been approved for subcutaneous (s.c.) use in Germany. Although all our adult patients on intravenous (i.v.) substitution were offered to switch to s.c. home therapy, approximately half of them refused to change. METHODS: To evaluate patients' attitude towards s.c. home therapy, a questionnaire was developed and sent to 125 patients. Questions had to be answered by ticking numbers on a Likert scale from 1 (not at all) to 8 (very much). Four scales of the Freiburg Personality Inventory (FPI) were added. From the 70 questionnaires returned (56%), 61 could be analysed (i.v. n = 28, s.c. n = 33). RESULTS: The i.v. treated patients were afraid of being busier with self-administration (6.9 +/- 2.1). This was not a serious concern in the s.c. treated group (3.6 +/- 1.8, p < 0.001). Many i.v. treated patients worried about severe adverse reactions at home (4.7 +/- 2.8), but patients in the s.c. group did not (1.7 +/- 1.0, p < 0.001). The statement "I dislike to puncture myself" reached 5.3 +/- 2.7 points in the i.v. treated group, but only 2.0 +/- 1.1 (p < 0.001) in the s.c. treated patients. As the main reason, patients on i.v. substitution considered s.c. therapy as inconvenient (48%). Secondly, they were afraid of side effects (31%). All patients on s.c. therapy appreciated the new treatment (7.2 +/- 1.0). The main advantage for them was an increase of flexibility (6.6 +/- 1.6). The FPI displayed lower values for s.c. treated patients in the scales "Physical Complaints" and "Emotional Lability." CONCLUSION: Those patients who had changed to s.c. therapy were highly satisfied. However, others preferred to stay on i.v. treatment for different reasons. Perception of inconvenience, anxiety of side effects, but also personal traits may play a role.

PMID: 16783533

Clinical Studies Main Page

Home

Important Safety Information

Immune Globulin Subcutaneous (Human), Vivaglobin^®, is indicated for the treatment of patients with primary immunodeficiency (PI).

As with all immune globulin products, Vivaglobin^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA. If anaphylactic or anaphylactoid reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Vivaglobin^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was injection-site reaction, consisting of mild or moderate swelling, redness, and itching. No serious local site reactions were observed, and reactions tended to decrease substantially after repeated use. Other adverse events irrespective of causality included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash.

As with all immune globulin (Ig) products, patients receiving Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions including fever, chills, nausea, and vomiting. On rare occasions, these reactions may lead to shock. Such patients should be monitored in a clinical setting during the initial administration.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella.

In clinical studies, administration of Vivaglobin^® has been shown to be safe and well tolerated in both adult and pediatric subjects. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels. Safety and efficacy were not studied in pediatric subjects under two years of age.

Please see accompanying full prescribing information for Vivaglobin^®.

Please see Patient Product Information

Please see full Prescribing Information

Important Safety Information

Please see accompanying full prescribing information for Vivaglobin®.

Please see accompanying full prescribing information for Vivaglobin^®.